Abstract:
Introduction: Patients with multiple myeloma (MM) have an increased risk of venous thromboembolic (VTE) complications. The first reports of high VTE rates date back to 1999 but became more apparent with the introduction of novel agents in the treatment of MM and mostly with immunomodulatory drugs (IMiDs; thalidomide, lenalidomide and pomalidomide). Areas covered: Currently thromboprophylaxis is recommended for patients who receive IMiDs-based regimens and the type of thrombophrophylaxis is based on patient-, disease- and treatment-related risk factors. Making the distinction between the intrinsic risk of thrombosis in MM and the effect of therapy is crucial. The use of aspirin, low molecular weight heparins and warfarin are the recommended drugs but despite their appropriate use the rates of VTE are not completely eliminated. Expert commentary: Research into biomarkers of increased coagulability and their incorporation in risk assessment models could identify patients most likely to benefit from thromboprophylaxis but such models are not widely used in myeloma. © 2016 Informa UK Limited, trading as Taylor & Francis Group.
Notes:
Cited By :1Export Date: 18 February 2017References: Falanga, A., Russo, L., Epidemiology, risk and outcomes of venous thromboembolism in cancer (2012) Hamostaseologie, 32, pp. 115-125;Cronin-Fenton, D.P., Søndergaard, F.F., Pedersen, L.A., Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006 (2010) Br J Cancer, 103 (7), pp. 947-953. , Sep;
Louzada, M.L., Majeed, H., Dao, V., Risk of recurrent venous thromboembolism according to malignancy characteristics in patients with cancer-associated thrombosis: a systematic review of observational and intervention studies (2011) Blood Coagul Fibrinol, 22, pp. 86-91;
(2015) Estimated incidence and mortality of multiple myeloma and immunoproliferative diseases in Europe in 2012 (both sexes), ,
http://eco.iarc.fr/eucan/Cancer.aspx?Cancer=39, cited, Dec, Available from;
(2015) Surveillance Epidemiology and End Results SEER 2006-2010, ,
http://www.seer.cancer.gob/statfacts/html/mulmy.html, cited, Nov, Available from;
De Stefano, V., Za, T., Rossi, E., Venous thromboembolism in multiple myeloma (2014) Semin Thromb Hemost, 40, pp. 338-347;
Isozumi, Y., Arai, R., Fujimoto, K., Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma (2013) PLoS ONE, 8 (5), p. e64369;
Kristinsson, S.Y., Thrombosis in multiple myeloma (2010) Hematol AM Soc Hematol Educ Program, 2010, pp. 437-444;
Leleu, X., Rodon, P., Hulin, C., MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs (2013) Thromb Haemost, 110, pp. 844-851;
Zangari, M., Tricot, G., Polavaram, L., Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone (2010) J Clin Oncol, 28 (1), pp. 132-135;
Kristinsson, S.Y., Pfeiffer, R.M., Björkholm, M., Thrombosis is associated with inferior survival in multiple myeloma (2012) Haematologica, 97 (10), pp. 1603-1607;
Gregersen, H., Nørgaard, M., Severinsen, M.T., Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism (2011) Eur J Haematol, 86 (2), pp. 129-134;
Kristinsson, S.Y., Pfeiffer, R.M., Bjorkhom, M., Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma (2008) Blood, 112 (9), pp. 3582-3586;
Za, T., De Stefano, V., Rossi, E., Multiple Myeloma GIMEMA-Latinum Region Working Group. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients (2013) Br J of Haematol, 160 (5), pp. 673-679;
Crowley, M.P., Eustace, J.A., O’Shea, S.I., Venous thromboembolism in patients with myeloma: incidence and risk factors in a “real-world” population (2014) Clin Appl Thromb Hemmost, 20 (6), pp. 600-606. , Sep;
Leebeek, F.W., Kruip, M.J., Sonneveld, P., Risk and management of thrombosis in multiple myeloma (2012) Thromb Res, 129, pp. S88-S92. , Apr;
Khorana, A.A., Kuderer, N.M., Culakova, E., Development and validation of a predictive model for chemotherapy associated thrombosis (2008) Blood, 111, pp. 4902-4907;
Dutia, M., White, R.H., Wun, T., Risk assessment models for cancer-associated venous thromboembolism (2012) Cancer, 118, pp. 3468-3476;
Cini, M., Zamagni, E., Valdré, L., Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin (2010) Eur J Haematol, 84, pp. 484-492;
Zamagni, E., Brioli, A., Tacchetti, P., Multiple Myeloma, Venous Thromboembolism and treatment related risk of thrombosis (2011) Semin Thromb Hemost, 37 (3), pp. 209-219;
Kwaan, H.C., Hyperviscosity in plasma cell dyscrasias (2013) Clin Hemorheol Microcirc, 55 (1), pp. 75-83;
Huang, H.L., Li, H., Li, D., Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma (2015) Blood Coagul Fibrinol, 26 (5), pp. 555-559. , Jul;
Palumbo, A., Palladino, C., Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance (2012) Ther Adv Drug Saf, 3 (5), pp. 255-266;
Baz, R., Li, L., Kottke-Marchant, K., The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma (2005) Mayo Clin Proc, 80, pp. 1568-1574;
Robak, M.L., Treliński, J., Chojnowski, K., Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma (2012) Med Oncol, 29 (5), pp. 3574-3580. , Dec;
Elabedin, H.M., Hassan, E.A., El Amir, M.A., The clinical utility of tissue factor level as biomarker in multiple myeloma (2012) J Americal Sci, 8 (12), pp. 255-261;
Geddings, J.E., Mackman, N., Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients (2013) Blood, 122 (11), pp. 1873-1880;
Owens, A.P., Mackman, N., III, Microparticles in hemostasis and thrombosis (2011) Circ Res, 108, pp. 1284-1297;
Nomura, S., Niki, M., Nisizawa, T., Microparticles as biomarkers of blood coagulation in cancer (2015) Biomark Cancer, 7, pp. 51-56;
Auwerda, J.J.L., Yuana, Y., Osanto, S., Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma (2011) Thromb Haemost, 105 (1), pp. 14-20. , Jan;
Cesarman-Maus, G., Braggio, E., Maldonado, H., Absence of tissue factor expression by neoplastic plasma cells in multiple myeloma (2012) Leukemia, 26, pp. 1671-1674;
Undas, A.L., Zubkiewicz-Usnarska, L., Helbig, G., Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications (2015) Blood Coagul Fibrinol, 26 (6), pp. 621-627;
Bagratuni, T., Kastritis, E., Politou, M., Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens (2013) Am J Hematol, 88, pp. 765-770;
Zangari, M., Berno, T., Zhan, F., Activated protein C resistance as measured by residual factor V after Russell’s viper venom and activated protein C treatment analyzed as a continuous variable in multiple myeloma and normal controls (2011) Blood Coagul Fibrinol, 22 (5), pp. 420-423;
Cesarman-Maus, G., Braggio, E., Fonseca, R., Thrombosis in multiple myeloma (MM) (2012) Hematology, 17, pp. S177-S180;
Carrier, M., Le Gal, G., Tay, J., Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis (2011) J Thromb Haemost, 9, pp. 653-663;
Dimopoulos, M.A., Swern, A.S., Li, J.S., Efficacy and safety of long term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (2014) Blood Cancer J, 4, p. e257;
Rajkumar, S.V., Jacobus, S., Callander, N.S., Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial (2010) Lancet Oncol, 11, pp. 29-37;
Rosovsky, R., Hong, F., Tocco, D., Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study (2013) Br J Haematol, 160 (3), pp. 351-358;
Zonder, J.A., Crowley, J., Hussein, M.A., Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232) (2010) Blood, 116 (26), pp. 5838-5841;
Palumbo, A., Hajek, R., Delforge, M., MM-015 Investigators. Continuous lenalidomide treatment in patients with recurrent multiple myeloma (2013) Cancer, 119 (20), pp. 3680-3686;
Larocca, A., Cavallo, F., Evangelista, A., Thromboprophylaxis for newly diagnosed multiple myeloma patients treated with lenalidomide-based regimens: a randomized phase iii study of aspirin vs enoxaparin (2011) Haematologica, 96, p. 210;
Hanaizi, Z., Flores, B., Hemmings, R., The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use (2015) Oncologist, 20 (3), pp. 329-334;
Richardson, P., Siegel, D., Vij, R., Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study (2014) Blood, 123 (12), pp. 1826-1832;
Fouquet, G., Tardy, S., Demarquette, H., Efficacy and safety profile of long term exposure to lenalidomide in patients with recurrent multiple myeloma (2013) Cancer, 119 (20), pp. 3680-3686;
Iida, S., Chou, T., Okamoto, S., Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma (2010) Int J Hematol, 92 (1), pp. 118-126. , Jul;
Attal, M., Lauwers-Cances, V., Marit, G., Lenalidomide maintenance after stem cell transplantation for multiple myeloma (2012) N Engl J Med, 366 (19), pp. 1782-1791;
Scott, L.J., Pomalidomide: a review of its use in patients with recurrent multiple myeloma (2014) Drugs, 74 (5), pp. 549-562. , Apr;
Miguel, J.S., Weisel, K., Moreau, P., Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomized, open-label, phase 3 trial (2013) Lance Oncol, 14 (11), pp. 1055-1066;
Dimopoulos, M.A., Leleu, X., Palumbo, A., Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma (2014) Leukemia, 28, pp. 1573-1585;
Leleu, X., Attal, M., Moreau, P., Phase II study of 2 modalities of pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. IFM 2009-02 (2010) ASH Annu Meet Abstr, 116 (21), p. 859;
Lacy, M.Q., Hayman, S.R., Gertz, M.A., Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM) (2010) Leukemia, 24, pp. 1934-1939;
Zangari, M.L., Fink, L., Zhan, F., Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens (2011) Clin Lymphoma Myeloma Leuk, 11 (2), pp. 228-236. , Apr;
Richardson, P.G., Siegel, D., Baz, R., Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib (2013) Blood, 121 (11), pp. 1961-1967;
Leleu, X., Attal, M., Arnulf, B., Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02 (2013) Blood, 121 (11), pp. 1968-1975;
Lacy, M.Q., Allred, J.B., Gertz, M.A., Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of two dosing strategies in dual-refractory disease (2011) Blood, 118, pp. 2970-2975;
Rupa-Matysek, J., Gil, L., Wojtasińska, E., Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma (2014) Thromb Res, 134 (2), pp. 404-411;
Abdullah, W.Z., Roshan, T.M., Hussin, A., Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin (2013) Blood Coagul Fibrinol, 24 (8), pp. 893-895;
Gandhi, A.K., Kang, J., Capone, L., Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function (2010) Current Cancer Drug Targets, 10, pp. 155-167;
Engelhardt, M., Terpos, E., Kleber, M., European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma (2014) Haematologica, 99 (2), pp. 232-242;
Lee, S.E., Jeon, Y.W., Yoon, J.H., Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients (2015) Thromb Res, 136 (5), pp. 974-979. , Nov;
Anaissie, E.J., Coleman, E.A., Goodwin, J.A., Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis (2011) Cancer, 118, pp. 549-557;
Lonial, S., Dimopoulos, M., Palumbo, A., Elotuzumab therapy for relapsed or refractory multiple myeloma (2015) N Engl J Med, 373, pp. 621-631;
Liu, Y.C., Szmania, S., Van Rhee, F., Profile of elotozumab and its potential in treatment of multiple myeloma (2014) Blood Lympaht Cancer, 2014 (4), pp. 15-27;
Laubach, J.P., Tai, Y.T., Richardson, P.G., Daratumumab granted breakthrough drug status (2014) Expert Opin Investig Drugs, 23 (4), pp. 445-452;
Plesner, T., Arkenau, H.-T., Lokhorst, H.M., Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma [abstract] (2014) Blood, 124, p. 21;
Palumbo, A., Cavo, M., Bringhen, S., Aspirin, warfarin or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial (2011) J Clin Oncol, 29 (8), pp. 986-993;
Dimopoulos, M.A., Palumbo, A., Attal, M., Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: a consensus statement (2011) Leukemia, 25 (5), pp. 749-760;
Palumbo, A., Rajkumar, S.V., San Miguel, J.F., International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation (2014) J Clin Oncol, 32 (6), pp. 587-600;
Terpos, E., Kleber, M., Engelhardt, M., European Myeloma Network guidelines for the management of multiple myeloma-related complications (2015) Haematologica, 100 (10), pp. 1254-1266;
Streiff, M.B., Bockenstedt, P.L., Cataland, S.R., Venous thromboembolic disease (2011) Clin Pract Guidel Oncol.J Natl Compr Canc Netw, 9, pp. 714-777;
Louzada, M., Mateos, M.V., Siqueira, L., Comparing the efficacy of aspirin or low molecular weight Heparin or vitamin K antagonists in the risk of thromboembolic events in patients with multiple myeloma treated with lenalidomide-based therapy (2015) Blood, 126, p. 23;
McCarthy, P., Owzar, K., Hofmeister, C., Lenalidomide after Stem-cell transplantation for multiple myeloma (2012) N Eng J Med, 366, pp. 1770-1781;
Palumbo, A., Hajek, R., Delforge, M., Continuous lenalidomide treatment for newly diagnosed Multiple Myeloma (2012) N Eng J Med, 366, pp. 1759-1769;
Lyman, G., Khorana, A., Kuderer, N., Venous thromboembolism prophylaxis and treatment in aptients with cancer: American society of clinical oncology clinical practice guideline update (2013) Clin Oncol, 31, pp. 2189-2204;
Palumbo, A., Larocca, A., Genuardi, M., Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial (2010) Haematologica, 95 (7), pp. 1144-1149;
Ay, C., Dunkler, D., Marosi, C., Prediction of venous thromboembolism in cancer patients (2010) Blood, 116, pp. 5377-5382;
Ay, C., Dunkler, D., Simanek, R., Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study (2011) J Clin Oncol, 29, pp. 2099-2103;
Lyman, G.H., Khorana, A.A., Kudere, N.M., Venous thromboemboembolism prophylaxis nad treatment in patients with cancer. Americal Soceity of Clinical Oncology clinical practice guidelin update (2013) J. Clin Oncol, 31, pp. 2189-2204;
Connolly, G.C., Khorana, A.A., Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score (2010) Thromb Res, 125, pp. S1-S7;
Crowley, M.P., Kevane, B., Eustace, J.A., Thromboprophylaxis in myeloma: what is happening outside of clinical trials? (2014) Ir Med J, 107 (9), pp. 281-284. , Oct;
Ferroni, P., Martini, F., Portarena, I., Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients (2012) Clin Lung Cancer, 13, pp. 482-487. , wol;
Dargaud, Y., Wolberg, A.S., Luddington, R., Evaluation of a standardized protocol for thrombin generation measurement using the calibrated automated thrombogram: an international multicentre study (2012) Thromb Res, 130 (6), pp. 929-934;
Gardiner, C., Harrison, P., Belting, P., Extracellular vesicles, tissue factor and thrombosis – discussion themes of the ISEV 2014 Educational Day (2015) J Extracell Vesicles, ,
http://www.journalofextracellularvesicles.net/index.php/jev/article/view..., Available from, Dec;
Manly, D., Wang, J., Glover, S.L., Increased microparticle tissue factor activity in cancer patients with venous thromboembolism (2010) Thromb Res, 125, pp. 511-512;
Nomura, S., Niki, M., Nisizawa, T., Microparticles as biomarkers in blood coagulation in cancer (2015) Biom in Cancer, 7, pp. 51-56;
Chaari, M., Ayadi, I., Rousseau, A., Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability (2014) BMC Cancer, 14, p. 991
Website
